Sistema de Salut de Catalunya
Institut Català de la Salut
[Morote J, Celma A] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Cirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Borque-Fernando Á] Department of Urology, Hospital Universitario Miguel Servet, IIS-Aragon, Zaragoza, Spain. [Esteban LM] Department of Applied Mathematics, Escuela Universitaria Politécnica La Almunia, Universidad de Zaragoza, Zaragoza, Spain. [Picola N] Department of Urology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain. [Muñoz-Rodriguez J] Department of Urology, Hospital Universitari Parc Taulí, Sabadell, Spain. [Paesano N] Departament de Cirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Clínica Creu Blanca, Barcelona, Spain. [Miró B] Unitat d’Estadística i Bioinformàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-07-16T12:21:35Z
2024-07-16T12:21:35Z
2024-07-10
5-alpha reductase inhibitor; Predictive model; Prostate cancer
Inhibidor de la 5-alfa reductasa; Modelo predictivo; Cáncer de próstata
Inhibidor de la 5-alfa reductasa; Model predictiu; Càncer de pròstata
Purpose To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI). Materials and methods A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2. Results The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783–0.842) and 0.849 (0.806–0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users. Conclusions The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment.
This research was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666). Open Access Funding provided by Universitat Autonoma de Barcelona.
Article
Published version
English
Pròstata - Càncer - Imatgeria; Pròstata - Càncer - Tractament; Inhibidors enzimàtics - Ús terapèutic; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Steroid Synthesis Inhibitors::5-alpha Reductase Inhibitors; DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms; Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de la síntesis esteroidea::inhibidores de la 5-alfa reductasa; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata; Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética
Springer
World Journal of Urology;42
https://doi.org/10.1007/s00345-024-05092-0
info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01666
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
